Certain diseases represent particular areas of focus for targeted cancer therapy. When developing molecular diagnostic assays, MolecularMD works from a clinical perspective, ensuring that the tests are designed to properly support the therapeutic requirements of these disease.
Our approach to assay development from the standpoint of the disease stems from work by MolecularMD scientific founders Dr. Brian Druker and Michael Heinrich. Both are leaders in the fields of targeted cancer therapies and clinically-based pharmacogenomic tests. Their expertise has led our team to important developments in molecular targets and the related molecular assays, which are often employed for patient selection and monitoring in clinical trials.
Our assay development efforts currently focus on: